Swedish Orphan Biovitrum AB (publ)
Sweden · SE0000872095 · reports in SEK · Europe
The answers
From the annual report for the year to Dec 31, 2024. Each line says what it is based on.
- Is it growing?Good
- Revenue +18% in the year to Dec 31, 2024, on the year before.
- Is it a good business?Fair
- It earned 9.6% on its shareholders' equity in the year to Dec 31, 2024.
- Is it safe?Good
- Equity is 53% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2024, consolidated, in SEK.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Revenue | SEK 15.5B | SEK 18.8B | SEK 22.1B | SEK 26.0B |
| Operating profit | SEK 3.7B | SEK 3.8B | SEK 4.1B | SEK 5.6B |
| Net profit to shareholders | n/a | n/a | SEK 2.4B | SEK 3.9B |
| Earnings per share | SEK 9.08 | SEK 8.92 | n/a | n/a |
| Cash from operations | SEK 5.5B | SEK 4.7B | SEK 4.5B | SEK 7.4B |
| Capital spending | SEK 47M | SEK 72M | SEK 873M | SEK 170M |
| Cash | SEK 1.0B | SEK 1.4B | SEK 904M | SEK 1.1B |
| Total assets | SEK 48.7B | SEK 52.5B | SEK 74.0B | SEK 75.4B |
| Equity | SEK 23.2B | SEK 26.5B | SEK 33.9B | SEK 40.3B |
What they do
In the company's own words, from the annual report.
Swedish Orphan Biovitrum AB (publ), organisationsnummer 556038-9321, moderbolaget och dess dotterföretag, (“koncernen”) är ett publikt börsnoterat globalt biopharmabolag inriktat på sällsynta sjukdomar.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.